NovoCure Limited (NVCR) 10-K 1 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 26, 2016	Jun. 30, 2015
Document Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	NVCR
Entity Registrant Name	Novocure Ltd
Entity Central Index Key	1,645,113
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		84,426,720
Entity Public Float			$ 0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 119,423	$ 57,613
Short-term investments	150,001	44,999
Restricted cash	87	61
Receivables and prepaid expenses	10,799	5,711
Inventories	13,594	3,446
Total current assets	293,904	111,830
Long-term Assets:
Property and equipment, net	6,552	3,732
Field equipment, net	6,029	2,017
Severance pay fund	79	70
Other long-term assets	772	227
Total long-term assets	13,432	6,046
Total Assets	307,336	117,876
Current Liabilities:
Trade payables	16,755	10,033
Other payables and accrued expenses	11,872	7,636
Total current liabilities	28,627	17,669
Long-term Liabilities:
Long-term loan, net of discount and issuance costs	23,097	0
Employee benefit liabilities	2,057	246
Other long-term liabilities	2,735	2,086
Total long-term liabilities	27,889	2,332
Total Liabilities	56,516	20,001
Commitments and Contingencies	0	0
Shareholders’ Equity:
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 83,778,581 shares and 13,431,414 shares at December 31, 2015 and December 31, 2014 respectively;	0	0
Preferred shares - No par value, Unlimited shares authorized; Issued and outstanding: Zero shares and 58,676,017 shares at December 31, 2015 and December 31, 2014 respectively;	0	0
Additional paid-in capital	640,406	374,375
Accumulated other comprehensive loss	(1,505)	0
Accumulated deficit	(388,081)	(276,500)
Total shareholders’ equity	250,820	97,875
Total Liabilities and Shareholders’ Equity	$ 307,336	$ 117,876

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	12 Months Ended
	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares
Statement Of Financial Position [Abstract]
Common stock, par value | (per share)	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	83,778,581	13,431,414
Common stock, shares outstanding	83,778,581	13,431,414
Preferred stock, par value | (per share)	$ 0	$ 0
Preferred stock, shares authorized	Unlimited	Unlimited
Preferred stock, shares issued	0	58,676,017
Preferred stock, shares outstanding	0	58,676,017

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net revenues	$ 33,087	$ 15,490	$ 10,359
Cost of revenues	20,610	10,036	7,013
Gross profit	12,477	5,454	3,346
Operating costs and expenses:
Research, development and clinical trials	43,748	40,381	34,797
Sales and marketing	38,861	21,177	16,406
General and administrative	33,864	24,052	16,602
Total operating costs and expenses	116,473	85,610	67,805
Operating loss	(103,996)	(80,156)	(64,459)
Financial expenses, net	(3,151)	(144)	(12,558)
Loss before income taxes	(107,147)	(80,300)	(77,017)
Income taxes	4,434	382	353
Net loss	$ (111,581)	$ (80,682)	$ (77,370)
Basic and diluted net loss per ordinary share	$ (3.67)	$ (6.46)	$ (6.73)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	30,401,603	12,490,017	11,498,392

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (111,581)	$ (80,682)	$ (77,370)
Other comprehensive loss, net of tax :
Pension benefit plan, net of tax	(1,505)
Total comprehensive loss	$ (113,086)	$ (80,682)	$ (77,370)

Statements of Changes in Shareh

Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands		Total	Over-Allotment	[3]	Series I Preferred Stock	Series J Preferred Stock	[4]	Ordinary Shares	Ordinary SharesOver-Allotment	Preferred Shares	Preferred SharesSeries I Preferred Stock	Preferred SharesSeries J Preferred Stock	Additional Paid-in Capital	Additional Paid-in CapitalOver-Allotment	[3]	Additional Paid-in CapitalSeries I Preferred Stock	Additional Paid-in CapitalSeries J Preferred Stock	[4]	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2012		$ 49,425											$ 167,873							$ (118,448)
Balance (in shares) at Dec. 31, 2012								11,419,786		45,315,765
Share-based compensation to employees		5,120											5,120
Exercise of options and warrants		2											2
Exercise of options and warrants (in shares)								471,635
Issuance of shares, net	[1]				$ 191,738											$ 191,738
Issuance of shares, net (in shares)											13,360,252
Issuance of warrants, net	[2]	2,864											2,864
Net loss		(77,370)																		(77,370)
Balance at Dec. 31, 2013		171,779											367,597							(195,818)
Balance (in shares) at Dec. 31, 2013								11,891,421		58,676,017
Share-based compensation to employees		4,624											4,624
Exercise of options and warrants		2,154											2,154
Exercise of options and warrants (in shares)								1,539,993
Net loss		(80,682)																		(80,682)
Balance at Dec. 31, 2014		97,875											374,375							(276,500)
Balance (in shares) at Dec. 31, 2014								13,431,414		58,676,017
Share-based compensation to employees		11,860											11,860
Exercise of options and warrants		2,038											2,038
Exercise of options and warrants (in shares)								731,665
Issuance of shares, net			$ 157,534			$ 94,599								$ 157,534			$ 94,599
Issuance of shares, net (in shares)									7,876,195			4,068,500
Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification (in shares)								(1,005,210)
Conversion of preferred shares to ordinary shares								62,744,517		(62,744,517)
Other comprehensive loss, net of tax benefit of $165		(1,505)																	$ (1,505)
Net loss		(111,581)																		(111,581)
Balance at Dec. 31, 2015		$ 250,820											$ 640,406						$ (1,505)	$ (388,081)
Balance (in shares) at Dec. 31, 2015								83,778,581
[1]	Net of issuance expenses of $2,440
[2]	Net of issuance expenses of $115
[3]	Net of issuance expenses (including underwriter fees) of $15,742
[4]	Net of issuance expenses of $319

Statements of Changes in Share7

Statements of Changes in Shareholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Other comprehensive loss, tax benefit	$ 165
Over-Allotment
Share issuance expenses	15,742
Warrant
Share issuance expenses	115
Series I Preferred Stock
Share issuance expenses	2,440
Series J Preferred Stock
Share issuance expenses	$ 319

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (111,581)	$ (80,682)	$ (77,370)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,153	1,962	1,216
Asset write-downs and impairment	46	23	19
Accrued interest expense	672		6,070
Share-based compensation to employees	11,860	4,624	5,120
Amortization of discount (premium)	329	(19)	5,432
Increase in receivables and prepaid expenses	(5,088)	(1,192)	(3,611)
Decrease (increase) in inventories	(10,148)	(1,554)	1,479
Increase in other long-term assets	(381)	(44)	(44)
Increase (decrease) in trade payables	6,961	(492)	5,695
Increase in other payables and accrued expenses	3,579	2,324	2,955
Increase in employee benefit liabilities, net	133	42	20
Increase in other long-term liabilities	581	764	302
Net cash used in operating activities	(99,884)	(74,244)	(52,717)
Cash flows from investing activities:
Purchase of property and equipment	(4,667)	(849)	(2,201)
Purchase of field equipment	(5,604)	(1,470)	(1,426)
Decrease (increase) in restricted cash	(26)	1,117	(1,019)
Proceeds from maturity of short-term investments	104,000	93,000	15,048
Purchase of short-term investments	(208,998)	(137,980)
Net cash provided by (used in) investing activities	(115,295)	(46,182)	10,402
Cash flows from financing activities:
Proceeds from issuance of shares, net	252,133		191,738
Proceeds from long-term loan, net	22,886		49,432
Repayment of long-term loans			(58,047)
Proceeds from issuance of other long-term loans		54	193
Repayment of other long-term loans	(63)	(63)
Exercise of options and warrants	2,038	2,154	2
Purchase of shares in respect of settlement	(5)
Net cash provided by financing activities	276,989	2,145	183,318
Increase (decrease) in cash and cash equivalents	61,810	(118,281)	141,003
Cash and cash equivalents at the beginning of the year	57,613	175,894	34,891
Cash and cash equivalents at the end of the year	119,423	57,613	175,894
Cash paid during the year for:
Income taxes	1,489	282	689
Interest	$ 1,688	25	7,131
Non-cash investing and financing activities:
Purchase of property and equipment		$ 239	$ 585

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1: Organization and Basis of Presentation a. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in Jersey and is principally engaged in the development, manufacture and commercialization of tumor treating fields (“TTFields”) for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company commenced selling and marketing activities in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015. b. On October 7, 2015, the Company completed its initial public offering (the “IPO”) by issuing 7,876,195 ordinary shares (including exercise of overallotments) and raising net proceeds of $157,534. In September 2015, the Company’s shareholders approved the restructuring of the Company’s share capital by converting the Company’s ordinary and preferred shares to no par value shares and by effecting a sub division of the issued and outstanding share capital of the Company based on a proportion of 1: 5.913 (“Share Split Ratio”), such that each ordinary and preferred share nominal value of £0.01 of the Company, was divided into 5.913 shares of such applicable class of shares of the Company each with no par value. It was also resolved to apply the Split Ratio to the Company’s outstanding options and warrants, in accordance with their terms. All share and per share information included in these consolidated financial statements has been retroactively adjusted to reflect the conversion to no par value shares and the Share Split Ratio.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	Note 2: Significant accounting policies The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”). a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S. dollar. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with Accounting Standards Codification No. 830-10, “Foreign Currency Matters.” All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation. d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less at the date acquired. e. Short-term investments and restricted cash: 1. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, “Investments-Debt and Equity Securities.” Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2015 and 2014, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any other than temporary impairment losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2015, no impairment losses other than temporary impairment losses have been identified. 2. Restricted cash: The Company has restricted cash used as security for bank guarantees related to the use of Company credit cards. f. Inventories: Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. The Company regularly evaluates the ability to realize the value of inventory. If actual demand for the Company’s delivery systems deteriorates, or market conditions are less favorable than those projected, inventory write-offs may be required. There were no inventory write-offs for the years ended December 31, 2015, 2014 and 2013. g. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life h. Field equipment under operating leases: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment which was determined to be two years. Field equipment consists of equipment being utilized under rental agreements accounted for in accordance with ASC 840 on a monthly basis as an operating lease, as well as “service pool” equipment. Service pool equipment is equipment owned and maintained by the Company that is swapped for equipment that needs repairs or maintenance by the Company while being rented by a patient. The Company records a provision for any excess, lost or damaged equipment when warranted based on an assessment of the equipment. Write-downs for equipment are included in cost of revenues. During the years ended December 31, 2015, 2014 and 2013, write downs for $36, $12 and $19, respectively, had been identified. i. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2015, no impairment losses have been identified. j. Other long-term assets: Long term lease deposits in respect of office rent and vehicles under operating leases and restricted deposits are presented in other long-term assets. k. Revenue recognition: The TTFields delivery system (“System”) for GBM, Optune, is comprised of two main components: (1) an Electric Field Generator (the “device”) and (2) Transducer Arrays and related accessories that are disposable supplies to the device (“disposables”). Title is retained by the Company for the device and the patient is provided replacement disposables and technical support for the device during the rental period. The device and disposables are always supplied and functioning together and are not sold on a standalone basis. Revenues are recognized when persuasive evidence of an arrangement exists, delivery of the system has occurred, the price is fixed or determinable and collectability is reasonably assured. The evidence of an arrangement generally consists of a prescription, a patient service agreement and the verification of eligibility and insurance with the patient’s third-party insurance company (“payer”). The Company generally bills third-party payers a monthly fee for use of the System by patients. As such, the Company takes assignment of benefits and risk of collection from the third-party payer. Patients have out-of-pocket costs for the amount not covered by their payer and the Company bills the patient directly for the amounts of their co-pays and deductible, subject to the Company’s patient assistance programs. For the reported periods, all revenues are recognized when cash is collected assuming that all other revenue recognition criteria have been met, as the price is not fixed or determinable and the collectability cannot be reasonably assured. The price is not fixed or determinable since the Company does not have sufficient history with payers to reliably estimate their individual payment patterns and as such cannot reliably estimate the amount that would be ultimately collected. Once sufficient history is established and the Company can reliably estimate the amounts that would be ultimately collected per payer/payer group and the above criteria are met, the Company will recognize revenues from the use of the System on an accrual basis ratably over the lease term. Revenues are presented net of indirect taxes, which include excise tax of $1,457 , $1,010, and $584 for the years ended December 31, 2015, 2014 and 2013, respectively, and other indirect tax of $818, $266 and $300 for the years ended December 31, 2015, 2014 and 2013, respectively. l. Charitable care: The Company provides Optune to patients who meet certain criteria under its charitable care policy without charge. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were: $1,376, $836 and $254 for the years ended December 31, 2015, 2014 and 2013, respectively. These estimates were determined by applying a ratio of costs to gross charges multiplied by the Company's gross charitable care charges. m. Research, development and clinical trials: Research, development and clinical trials, including direct and allocated expenses are expensed as incurred. n. Shipping and handling costs: The Company does not bill its customers for shipping and handling costs associated with shipping its delivery systems to its customers. These direct shipping and handling costs of $1,385, $553 and $431 for the years ended December 31, 2015, 2014 and 2013, respectively are included in selling and marketing costs. o. Accounting for share-based payments: The Company accounts for share-based compensation in accordance with ASC 718, “Compensation—Stock Compensation.” ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation costs net of a forfeiture rate only for those shares expected to vest using the accelerated method over the requisite service period of the award, which is generally the option vesting term of four years. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price expected, expected volatility and the expected option term. Prior to the IPO, the fair value of ordinary shares underlying the options was historically determined by management and the board of directors. Because there was no public market for the Company’s ordinary shares, the board of directors determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including operating and financial performance, the lack of liquidity of share capital, general and industry specific economic outlook and valuations performed amongst other factors. For the period from January 1, 2015 through the IPO and for the two years ended December 31, 2014, the Company’s board of directors determined the fair value of ordinary shares for the reported periods, among other factors, based on valuations performed using the hybrid method, which is the hybrid between the probability weighted expected return method (PWERM) and the option pricing method, as the Company began to consider IPO activities commencing in January 2012. The computation of expected volatility is based on actual historical share price volatility of comparable companies. Expected term of options granted is calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms. p. Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the long-term loans approximate fair value. The Company accounts for certain assets and liabilities at fair value under ASC 820, “Fair Value Measurements and Disclosures.” Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument are categorized as Level 3. q. Basic and diluted net loss per share: The Company applies the two class method as required by ASC 260-10, “Earnings Per Share.” ASC 260-10 requires the income or loss per share for each class of shares (ordinary and preferred shares) to be calculated assuming 100% of the Company’s earnings are distributed as dividends to each class of shares based on their contractual rights. No dividends were declared or paid during the reported periods. According to the provisions of ASC 260-10, the Company’s preferred shares are not participating securities in losses and, therefore, are not included in the computation of net loss per share. Basic and diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period, in accordance with ASC 260-10. Basic and diluted net loss per ordinary share was the same for each period presented as the inclusion of all potential ordinary shares (all preferred shares, options and warrants) outstanding was anti-dilutive. r. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes.” ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is “more likely than not” to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense. s. Concentration of risks: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term investments. Cash and cash equivalents and restricted cash are invested in major banks or financial institutions in Jersey, the United States, Israel, Luxemburg, Switzerland, Japan and Germany. Such investments may be in excess of insured limits and are not insured in other jurisdictions. Generally, these investments may be redeemed upon demand and, therefore, bear minimal risk. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. In 2015, two payers represented $5,595 and $2,512 or 17% and 8% of net revenues, respectively. In 2014, the same two payers represented $2,372 and $2,014 or 15% and 12% of net revenues, respectively and in 2013, the same two payers represented $2,056 and $1,160 or 18% and 10% of net revenues, respectively. t. Severance pay: The majority of the Company’s employees in Israel have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (“Section 14”). Pursuant to Section 14, the Company’s employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. Neither severance pay liability nor severance pay fund under Section 14 for such employees is recorded on the Company’s consolidated balance sheet. With regard to employees in Israel that are not subject to Section 14, the Company’s liability for severance pay is calculated pursuant to Israeli Severance Pay Law, based on the most recent salary of the relevant employees multiplied by the number of years of employment as of the balance sheet date. These employees are entitled to one month’s salary for each year of employment or a portion thereof. The Company’s liability for these employees is fully provided for through monthly deposits to the employees’ pension and management insurance policies and an accrual. The value of these deposits is recorded as an asset on the Company’s consolidated balance sheet. The carrying value of the deposited funds is based on the cash surrender value and includes profits accumulated up to the balance sheet date. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Israeli Severance Pay Law. Severance pay expense for the years ended December 31, 2015, 2014 and 2013 amounted to $356, $307 and $288, respectively. u. Retirement and pension plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. The Company does not make any matching contributions to the plan. The Company has a defined benefit plan with a pension fund for its Swiss employees, whereby the employee and the Company contribute to the pension fund. The Company accounts for its obligation, in accordance with ASC 715, "Compensation – Retirement Benefits" (see note 9). The pension expense for the years ended December 31, 2015, 2014 and, 2013 was $404, $205 and $70, respectively. v. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2015 and 2014, the Company was not a party to any ligation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. w. Other comprehensive loss: The Company accounts for comprehensive loss in accordance with ASC 220, "Comprehensive Income". This statement establishes standards for the reporting and display of comprehensive loss and its components. Comprehensive loss generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive loss, net of taxes, at December 31, 2015 relates to a pension liability. x. Recently issued accounting pronouncements: In November 2015, the Financial Accounting Standards Board ("FASB") issued an accounting standards update for income taxes, which requires deferred tax assets and liabilities to be classified as noncurrent on the consolidated balance sheets. The new accounting guidance is effective for annual reporting periods beginning after December 15, 2016 and interim periods therein. Early adoption is permitted for all entities as of the beginning of interim or annual reporting periods. The Company early adopted the new guidance for the year ended December 31, 2015 and has applied the amendment on a prospective basis. In April 2015, the FASB amended the existing accounting standards for imputation of interest. The amendments require that debt issuance costs related to a recognized debt liability be presented on the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. The Company is required to adopt the guidance in the first quarter of fiscal 2017. Early adoption is permitted. The amendments should be applied retrospectively with the adjusted balance sheet of each individual period presented, in order to reflect the period-specific effects of applying the new guidance. The Company early adopted the new guidance for the year ended December 31, 2015.The adoption of this standard resulted in a reclassification of the debt issuance costs of $1.4 million for the year ended December 31, 2015, from Other long-term assets to Long-term loan, net of discount and issuance costs on the consolidated balance sheet. There was no impact to the consolidated statements of operations, comprehensive loss or cash flows. In May 2014, the FASB amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued an accounting standard update for a one-year deferral of the effective date, with an option of applying the standard on the original effective date, which for the Company is the first quarter of fiscal 2017. In accordance with this deferral, the Company is required to adopt these amendments no later than the first quarter of fiscal 2018. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is continuing to evaluate the impact of these amendments and the transition alternatives on its consolidated financial statements.

Cash and Cash Equivalents and S

Cash and Cash Equivalents and Short Term Investments	12 Months Ended
	Dec. 31, 2015
Marketable Securities Current [Abstract]
Cash and Cash equivalents and Short-term investments	Note 3: Cash and Cash equivalents and Short-term investments a. Cash and cash equivalents: December 31, 2015 2014 Cash $ 75,421 $ 47,614 Money market funds 44,002 - U.S. treasury bills - 9,999 Total cash and cash equivalents $ 119,423 $ 57,613 b. Short-term investments The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $150,001 and $44,999, as of December 31, 2015 and 2014, respectively and their estimated fair value as of December 31, 2015 and 2014 was $149,978 and $44,999, respectively.

Receivables and Prepaid Expense

Receivables and Prepaid Expenses	12 Months Ended
	Dec. 31, 2015
Receivables And Prepaid Expenses [Abstract]
Receivables and Prepaid Expenses	Note 4: Receivables and prepaid expenses December 31, 2015 2014 Advances and receivables from suppliers $ 7,323 $ 4,262 Government authorities 1,955 501 Prepaid expenses 1,290 853 Others 231 95 $ 10,799 $ 5,711

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Note 5: Inventories December 31, 2015 2014 Raw materials $ 3,518 $ 526 Work in process 4,618 1,280 Finished goods 5,458 1,640 $ 13,594 $ 3,446

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Note 6: Property and equipment, net December 31, 2015 2014 Cost: Computers and laboratory equipment $ 6,734 $ 3,745 Office furniture 1,245 995 Production equipment 857 - Leasehold improvements 1,653 1,343 Total cost $ 10,489 $ 6,083 Accumulated depreciation and amortization (3,937 ) (2,351 ) Depreciated cost $ 6,552 $ 3,732 Depreciation expense was $1,348, $886 and $520 for the years ended December 31, 2015, 2014 and 2013, respectively. In 2015, the Company implemented a new ERP system and capitalized costs incurred related to the system according to FASB ASC 350-40, "Accounting for the costs of Computer Software Developed or Obtained for Internal Use". As of December 31, 2015, the Company capitalized an accumulated amount of $2,803. Amortization for the year ended December 31, 2015 was $250.

Field Equipment, Net

Field Equipment, Net	12 Months Ended
	Dec. 31, 2015
Field Equipment [Abstract]
Field Equipment, Net	Note 7: Field equipment, net December 31, 2015 2014 Field equipment $ 9,226 $ 3,942 Less: accumulated depreciation (3,197 ) (1,925 ) Field equipment, net $ 6,029 $ 2,017 Depreciation expense was $1,555, $1,076 and 696 for the years ended December 31, 2015, 2014 and 2013, respectively.

Other Payables and Accrued Expe

Other Payables and Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Other Payables and Accrued Expenses	Note 8: Other payables and accrued expenses December 31, 2015 2014 Employees and payroll accruals $ 8,258 $ 5,846 Taxes payable and others 2,850 693 Provision for settlement - 1,000 Other 764 97 $ 11,872 $ 7,636

Employee benefit obligations

Employee benefit obligations	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Obligations	Note 9: Employee benefit obligations The Company sponsors a defined benefit plan (the “Swiss Plan”) for all its employees in Switzerland for retirement benefits, as well as benefits on death or long-term disability. The liability in respect of the Swiss Plan is the projected benefit obligation calculated using the projected unit credit method. The projected benefit obligation as of December 31, 2015 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee service rendered before that date. Swiss Plan assets are recorded at fair value. Pension expense is presented in the payroll expenses in the various functions in which the employees are engaged. Actuarial gains and losses arising from differences between the actual and the expected return on the Swiss Plan assets are recognized in accumulated other comprehensive income (loss) and amortized over the requisite service period. The plan is part of a collective pension foundation run by an insurance company. The Company and the employees pay retirement contributions, which are defined as a percentage of the employees’ covered salaries. The foundation, in turn, has all its risks (disability, death, longevity) and future benefits managed and guaranteed by the insurance company. Interest is credited to the employees’ account at the minimum rate provided in the Swiss Plan, payment which is guaranteed by the insurance contract, which represents the Swiss Plan’s primary asset. The targeted allocation for these funds is as follows: Asset Allocation by Category as of December 31, 2015: Asset Category: Asset allocatio n Debt Securities 75 Real Estate 16 Equity Securities 3 Others 6 Total 100 The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2015: December 31, 2015 Change in Benefit Obligation Projected benefit obligation at beginning of year $ - Interest cost 47 Company service cost 312 Employee contributions 189 Prior service cost 158 Benefits paid 4,023 Actuarial loss 1,494 Projected benefit obligation at end of year $ 6,223 Change in Plan Assets Fair value of plan assets at beginning of year $ - Actual return on plan assets (63 ) Employer contributions 284 Employee contributions 189 Benefits paid 4,023 Fair value of plan assets at end of year $ 4,433 Funded Status at End of year Excess of obligation over assets $ (1,790 ) Change in Accrued Benefit Liability Accrued benefit asset/(liability) at beginning of year $ - Company contributions made during year 284 Net periodic benefit cost for year (404 ) Net decrease in accumulated other comprehensive loss (1,670 ) Accrued benefit liability at end of year $ (1,790 ) December 31, 2015 Non - current plan assets $ 4,433 Non - current liability 6,223 Accrued benefit liability at end of year $ (1,790 ) Projected Benefit Payments 2016 $ 8 2017 13 2018 19 2019 25 2020 32 2021 - 2024 $ 264 The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2015. The level of inputs used to measure fair value was Level 2. Year December 31, 2015 Net Periodic Benefit Cost Service cost $ 312 Interest cost 47 Expected return on plan assets (38 ) Amortization of prior service costs 14 Amortization of transition obligation 69 Total net periodic benefit cost $ 404 Weighted average assumptions: Discount rate as of December 31 1.00% Expected long-term rate of return on assets 1.00% Rate of compensation increase 1.00% Mortality and disability assumptions BV G (*) Mortality data used for actuarial calculation.

Long - Term Loan, Net of Discou

Long - Term Loan, Net of Discount and Issuance Costs	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long - Term Loan, Net of Discount and Issuance Costs	Note 10: Long-term loan, net of discount and issuance costs In January 2013, the Company entered into a Credit Agreement (the “Credit Agreement”) with the lenders named therein (the “Lenders”) for a three-year term (the “Credit Facility”). Upon the closing of the Credit Agreement in January 2013, the Company withdrew the full $52,000 and issued the Lenders 975,644 warrants to purchase preferred H shares (converted to Ordinary shares as described in note 14a) at an exercise price of $18.77 per share. The Credit Facility accrued an 11% per year payment-in-kind interest charge, capitalized as additional principal quarterly, and a quarterly cash coupon of 3-month US$ LIBOR, subject to a LIBOR floor of 0.5% plus 1.5% per annum. The Company recorded the relative fair value of the warrants of $2,864 as shareholder’s equity and as a discount to the related loan outstanding. The total discount of $4,927 (including an original issue discount of $2,000) and additional deferred issuance costs of $500 in respect of the loan are amortized to interest expense over the three-year term using the effective interest method. In December 2013, the Company repaid the entire outstanding Credit Facility of $58,000 of principal and accrued interest. Upon repayment of the Credit Facility, the discount and the deferred issuance costs were recorded immediately as interest expense. Financial expenses related to the Credit Facility for the year ended December 31, 2013 were $12,577. In January 2015, the Company entered into a five-year term loan agreement (the “Loan Agreement”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company may draw the remaining $75,000 at its option at any time through June 30, 2016. Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year, respectively, from the initial funding date. The entire outstanding principal loan is due on January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Loan Agreement sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis commencing March 31, 2015 through the term of loan. As of December 31, 2015, the Company complies with its debt covenants. The total discount of $491 and additional issuance costs of $1,739 are presented net of the loan and are amortized to interest expense over the five year term of the loan using the effective interest method.

Other Long-term Liabilities

Other Long-term Liabilities	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Other Long-term Liabilities	Note 11: Other long-term liabilities December 31, 2015 2014 Deferred rent liability $ 785 $ 590 Leasehold improvements financing and other (see a and b below) 254 321 Unrecognized tax benefits (Note 13e) 1,565 308 Provision for settlement (Note 14c) - 867 Other 131 - $ 2,735 $ 2,086 a. In July 2013, the Company entered into a loan agreement with the landlord of its facility in Switzerland whereby the landlord will offer a loan of up to CHF 400 for the purpose of financing leasehold improvements in the facility. As of December 31, 2015 and 2014, the Company received CHF 220 ($232) of this financing. The principal and interest is due in monthly payments from January 1, 2014 through December 31, 2018 and bears an annual interest of 5%. b. In May 2013 and January 2014, the Company entered into an agreement with the landlord of one of its facilities in the U.S. and an agreement with a leasing company of $226 for the purpose of financing leasehold improvements in the facility and a lease of machinery, respectively. The loan and interest is due in monthly payments from June 1, 2013 through May 1, 2023 and bears an annual interest of 7%. The above principal leasehold improvement financing repayments as of December 31, 2015 are as follows: 2016 $ 63 2017 69 2018 73 2019 23 2020 24 Thereafter 65 317 Less: current portion of long-term loans (63 ) Long-term loans, net of current portion $ 254

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Note 12: Commitments and contingent liabilities a. The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2023. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2018. Future minimum lease payments under non-cancelable operating leases as of December 31, 2015, are as follows: 2016 $ 2,320 2017 2,171 2018 1,152 2019 987 2020 591 Thereafter 1,261 $ 8,482 Lease and rental expense for the years ended December 31, 2015, 2014 and 2013 was $2,194, $1,794, and $1,356, respectively. As of December 31, 2015 and 2014 the Company pledged bank deposits of $133 and $130, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $283 and $281, respectively. b. For an additional commitment, see note 14c.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 13: Income taxes a. The provision (benefit) for income taxes is comprised of: Loss before income taxes: Year ended December 31, 2015 2014 2013 United States (U.S.) $ (55,087 ) $ (22,015 ) $ (15,698 ) Non-U.S. (52,060 ) (58,285 ) (61,319 ) $ (107,147 ) $ (80,300 ) $ (77,017 ) Income tax expense (benefit): Year ended December 31, 2015 2014 2013 Current: United States $ 891 $ 65 $ (18 ) Non-U.S. 3,678 324 308 Total current 4,569 389 290 Deferred: Non-U.S. (135 ) (7 ) 63 Total deferred $ (135 ) $ (7 ) $ 63 $ 4,434 $ 382 $ 353 b. The Company is a resident taxpayer in Jersey and as such is not generally subject to Jersey tax on remitted foreign earnings. Therefore, the Company has chosen to present the note below using the notional U.S. federal income tax rate of 35% when presenting the Company's reconciliation of the income tax provision. A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2015 2014 2013 Loss before income taxes $ (107,147 ) $ (80,300 ) $ (77,017 ) Statutory tax rate 35 % 35 % 35 % Notional U.S. federal income taxes at statutory rate $ (37,501 ) $ (28,105 ) $ (26,956 ) Non-deductible expenses 2,621 1,242 1,411 Foreign tax rate differential 18,573 20,261 20,965 Change in valuation allowance 19,550 7,226 4,727 Unrecognized tax expense (benefit) 1,257 (242 ) 206 Other (66 ) - - Income tax expenses $ 4,434 $ 382 $ 353 Effective tax rate -4.14 % -0.48 % -0.46 % The Company's tax rate is affected by the tax rates in the jurisdictions in which the Company operates, the relative amount of income earned by jurisdiction, jurisdictions with a statutory tax rate less than the U.S. tax rate of 35% and the relative amount of losses or income for which no tax benefit or expense was recognized due to a valuation allowance. c. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax assets: Allowance for doubtful accounts $ 11,504 $ 4,001 Revenue recognition (timing differences) 21,972 9,042 Net operating loss carryforwards 347 850 Other temporary differences 952 482 Total gross deferred tax assets $ 34,775 $ 14,375 Less: valuation allowance (33,476 ) (13,926 ) Total deferred tax assets $ 1,299 $ 449 Deferred tax liabilities: Fixed assets 1,008 442 Total gross deferred tax liabilities $ 1,008 $ 442 Net deferred tax assets $ 291 $ 7 d. Carryforward loss: As of December 31, 2015, the Company's Luxembourg subsidiary has $1.2 million of net operating loss carry forwards (NOLs) available for utilization in future years. e. Accounting for uncertainty in income taxes (“ASC 740”): A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2015 2014 Balance at beginning of the year $ 308 $ 549 Additions for tax positions related current year 848 79 Additions for tax positions related to prior years 409 - Reduction related to lapse of applicable statute of limitations - (320 ) Balance at the end of the year $ 1,565 $ 308 The Company recognizes interest and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2015, 2014 and 2013, the Company accrued $26, $2 and $20, respectively, for interest and penalties expenses related to uncertain tax positions. f. The Company's Israeli subsidiary is currently under an income tax audit for the tax years 2011 through 2013. There are no other ongoing income tax audits.

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2015
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Share Capital	Note 14: Share capital Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2015 2014 Ordinary shares no par value 83,778,581 13,431,414 Series A Convertible Preferred shares no par value - 4,177,235 Series B Convertible Preferred shares no par value - 4,590,439 Series C Convertible Preferred shares no par value - 2,261,666 Series D Convertible Preferred shares no par value - 4,451,913 Series E Convertible Preferred shares no par value - 7,790,861 Series F Convertible Preferred shares no par value - 12,864,362 Series G Convertible Preferred shares no par value - 5,106,269 Series H Convertible Preferred shares no par value - 4,073,020 Series I Convertible Preferred shares no par value - 13,360,252 Total - 58,676,017 a. Investment rounds: 1) Series I Convertible Preferred shares: In 2013, the Company sold to investors 13,360,252 Series I Convertible Preferred shares at a purchase price of $14.53 per share, for total consideration of $191,738, net of issuance expenses. Prior to conversion of the Series I Convertible Preferred shares into ordinary shares as a result of the IPO, Series I Convertible Preferred shares were senior to the other series of preferred shares on payment of the liquidation preference ($14.53 per share), but otherwise had similar participating preferred rights, dividend rights and voting rights to the other series of preferred shares. 2) Series J Preferred shares: In June 2015, the Company sold to investors 4,068,500 Series J Convertible Preferred shares at a price per share of $23.33, for a total consideration of $94,599 (net of issuance expenses of $319). Prior to conversion of the Series J Convertible Preferred shares into ordinary shares as a result of the IPO, such shares were senior to the other series of preferred shares on payment of the liquidation preference (equal to $23.33 per share), but otherwise had similar participating preferred rights, dividend rights and voting rights of the other series of preferred shares. b. Rights, preferences and restrictions: On October 7, 2015, the Company completed the IPO of its ordinary shares by issuing 7,876,195 ordinary shares (including exercise of overallotments) and raising net proceeds of $157,534, at which time the Series A through J Convertible Preferred shares converted into ordinary shares and ceased to exist. The rights, preferences and restrictions of the Series A through J Convertible Preferred shares were, and the rights, preferences and restrictions of ordinary shares are, as follows: Conversion — Each Convertible Preferred share was convertible into ordinary shares (i) at any time at the holder’s option or (ii) automatically upon a qualified initial public offering, which is defined in the Company’s articles of association in effect prior to the IPO as an offering in which the aggregate gross proceeds received by the Company are (1) at least $50,000 if the equity securities of the Company that are sold in such offering are listed or traded on the New York Stock Exchange (NYSE) or the National Association of Securities Dealers Automated Quotations (NASDAQ) or (2) at least $100,000 if the equity securities of the Company that are sold in such offering are listed or traded on any other public stock exchange. The IPO constituted a qualified initial public offering and, therefore, triggered conversion of the Series A through J Convertible Preferred shares. Each of the Series A, B, C, D, E, F, G, H, I and J Convertible Preferred shares converted to ordinary shares on a 1-for-1 ratio, following adjustment for any recapitalizations, splits, ordinary share dividends and similar standard anti-dilution events. Dividend rights — The holders of Series A through J Convertible Preferred shares were entitled to receive on a pari passu Liquidation preference — The holders of Series A through J Convertible Preferred shares have a liquidation preference equal to $1.52, $1.09, $1.77, $1.80, $1.80, $2.23, $8.64, $13.5, $14.53, and $23.33 per share, respectively, plus any declared but unpaid dividends. Preferred shareholders were entitled to their liquidation preferences based on their seniority. Series J Convertible Preferred shareholders would have been the first to receive their liquidation preferences and they would have been followed by the holders of Series I, H, G, F, E, D, C, B and A Convertible Preferred shares in turn. Voting rights — Each holder of ordinary shares is and, prior to conversion into ordinary shares as a result of the IPO, each holder of Series A, B, C, D, E, F, G, H, I or J Convertible Preferred shares was, entitled to one vote. c. Settlement agreement: In February 2015, the Company entered into a settlement agreement (the “Settlement Agreement”) with a third party to resolve certain potential disputes regarding intellectual property developed by the Company’s founder and previously assigned to the Company. In exchange for a release of potential disputes from the third party, the Company paid $1,000 on execution of the Settlement Agreement and agreed to pay an additional $1,000 (the “Additional Payment”) at the earliest of (i) 18 months after signing of the Agreement, (ii) an IPO or (iii) the earlier of consummation of a merger/acquisition (“M&A”) or achievement of a Cumulative Net Sales milestone of $250,000 (as defined pursuant to the Agreement). The Company also agreed to pay an additional $5,500 on the earlier of (i) achievement of the Cumulative Net Sales milestone per above or (ii) consummation of a merger or acquisition transaction. In addition, the Company agreed to issue 1,005,210 ordinary shares (the “Settlement Shares”) to the third party and to grant to the third party options to purchase 1,005,210 ordinary shares (the “Settlement Options”) that are fully vested and at no cost. The Settlement Options terminate at the earlier of (i) 12 months subsequent to an IPO or (ii) immediately prior to a merger or acquisition transaction. In February 2015, the Company contemporaneously entered into a Letter of Agreement (“Letter of Agreement”) with a Company founder and a related party of the founder (together, the “Founder”) pursuant to which the Founder indemnified the Company for compensation incurred to the third party by providing 2,010,420 ordinary shares which were redeemed and cancelled (the “Redeemed Shares”) in March 2015 to the Company at par value. The Founder also may be obligated to pay an additional $2,000 in cash to the Company upon its request out of the net proceeds from the sale of any ordinary shares by the Founder in a private transaction or following the consummation of a qualified initial public offering (as defined above in Note 14a—Conversion) in an open market transaction if the closing price of the ordinary shares is at least 80% of the price per share for which the ordinary shares were sold in the IPO (after deducting underwriting discounts and commissions and offering expenses). In March 2015, the Company provided the Settlement Shares and Settlement Options to the third party. On October 7, 2015, the Company completed the IPO of its ordinary shares and the Additional Payment was paid in October 2015. Accordingly, for the year ended December 31, 2014, in accordance with ASC 450, the Company recorded a provision for a net settlement expense of $1,867 in general and administrative expense, reflecting the present value of the cash obligation of $2,000 and the fair value of the Settlement Shares issued and Settlement Options granted to the third party, net of the fair value of the Redeemed Shares provided by the Founder as consideration, which amounted to nil as presented in the statement of shareholder’s equity, in connection with the indemnification provided and the Letter of Agreement. d. Warrants: As part of the Series B, C, D and E Convertible Preferred share investment agreements, the investors received warrants to purchase ordinary shares. The Company accounted for these warrants as equity instruments based on the guidance of ASC 815, “Derivatives and Hedging”, ASC 480-10, “Distinguishing Liabilities from Equity”, its related FASB staff positions, ASC 815-40 “Contracts in Entity’s Own Stock” and the AICPA Technical Practice Aid for accounting for preferred shares and warrants, including the roadmap for accounting for freestanding financial instruments indexed to, and potentially settled in, a company’s own stock. Significant terms of the warrants to purchase ordinary shares that were issued to purchasers of the Series B, C, D and E Convertible Preferred shares are as follows as of December 31, 2015 and 2014: Warrants for ordinary shares Exercise per share Expiration date 2015 2014 October 11, 2015 (1) - 565,411 3.54 May 8, 2016 (1) 1,108,050 1,112,983 3.59 July 31, 2017 556,678 556,678 3.59 January 22, 2018 556,678 556,678 3.59 July 21, 2018 834,355 834,355 3.59 3,055,761 3,626,105 ( 1 ) Warrants to purchase 570,344 ordinary shares were exercised in 2015, resulting in the issuance of 570,344 ordinary shares. Pursuant to the Credit Agreement (see Note 10), the Company issued the Lenders 975,644 warrants to purchase Series H Convertible Preferred shares at an exercise price of $18.77 per share. The warrants were exercised on a cashless basis in January 2016. e. Share option plans: In 2003, the Company and its shareholders approved and adopted the 2003 Share Option Plan (the “2003 Plan”), which provided for the grant of options to the Company’s officers, directors, employees and advisors. The options granted generally have a four-year vesting period and expire ten years after the date of grant. Since March 2013, when the 2003 Plan expired, the Company has made grants pursuant to the 2013 Share Option Plan (as described below) and, following completion of the IPO in October 2015, all future equity grants will be made under the 2015 Omnibus Incentive Plan (as described below); however, any awards granted under the 2003 Plan that were outstanding as of the IPO continue to be subject to the terms and conditions of the 2003 Plan and the applicable option award agreement. In 2013, the Company and its shareholders approved and adopted the 2013 Equity Incentive Share Option Plan (the “2013 Plan”), which provided for the grant of options to the Company’s officers, directors, advisors, management and other key employees. The options granted generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2013 Plan that are cancelled or forfeited before expiration become available for future grant. In February and March 2015, the Company’s board of directors and its shareholders approved an increase in the number of ordinary shares reserved for grant of options pursuant to the 2013 Plan by 2,956,500 ordinary shares to 13,198,224 ordinary shares. Following completion of the IPO in October 2015, all future equity grants will be made under the 2015 Omnibus Incentive Plan (as described below); accordingly, as of December 31, 2015, there are no options available for future grants under the 2013 Plan. Any awards granted under the 2013 Plan that were outstanding as of the IPO continue to be subject to the terms and conditions of the 2013 Plan and the applicable option award agreement. In August 2015, the Company’s board of directors adopted and established the 2015 Omnibus Incentive Plan (the “2015 Plan”). The Company’s shareholders approved the 2015 Plan in September 2015. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards. The options granted generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant. On December 31, 2015, in accordance with the terms of the 2015 Plan, the number of shares available for issuance under the 2015 Plan automatically increased by 4% of the Company’s outstanding ordinary shares as of December 30, 2015. As a result, the number of shares available for issuance under the 2015 Plan increased from 12,900,000 shares to 16,251,143 shares. As of December 31, 2015, 14,947,667 ordinary shares are available for grant under the 2015 Plan. The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants, with the following underlying assumptions: Year ended December 31, 2015 2014 2013 Expected term (years) 6.25 6.25 6.25 Expected volatility 59%-65.8% 73.1%-75.3% 70.4%-75.9% Risk-free interest rate 1.74%-2.05% 1.9%-2.3% 1.4%-2.0% Dividend yield 0% 0% 0% A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2015 and changes during the year ended on that date is presented below: Year ended December 31, 2015 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 7,426,159 3.98 Granted 3,108,393 18.01 Exercised (183,911 ) 3.08 Forfeited and cancelled (215,812 ) 8.81 Outstanding at end of year 10,134,829 8.20 144,776 Exercisable options 5,521,406 3.04 106,684 Vested and expected to vest 10,007,130 8.11 143,835 The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2015, 2014 and 2013, was comprised as follows: Year ended December 31, 2015 2014 2013 Cost of revenues $ 174 $ 32 $ 52 Research, development and clinical trials 2,529 820 1,137 Sales and marketing 2,496 1,104 791 General and administrative 6,661 2,668 3,140 Total share-based compensation expense $ 11,860 $ 4,624 $ 5,120 As of December 31, 2015, there were unrecognized compensation costs of $25,008, which are expected to be recognized over a weighted average period of approximately 3.39 years. The weighted average grant date fair values of the Company’s options granted during the years ended December 31, 2015, 2014 and 2013 were $10.64, $5.08 and $4.59 per share, respectively. The weighted average grant date fair values of the Company’s unvested options for the years ended December 31, 2015,2014 and 2013 were $8.66, $4.26 and $3.42 per share, respectively, and the unvested options for the years ended December 31, 2015,2014 and 2013 were 4,613,423, 2,934,974 and 3,125,543, respectively. The weighted average grant date fair values of the Company’s vested options during the years ended December 31, 2015, 2014 and 2013 were $3.66, $2.89 and $2.26, respectively, and the vested options for the years ended December 31, 2015,2014 and 2013 were 1,235,880, 1,166,974 and 1,030,933, respectively. The weighted average grant date fair values of the Company’s options forfeited and cancelled during the years ended December 31, 2015, 2014 and 2013 were $ 5.73, $3.59 and $1.84, respectively. The aggregate intrinsic values for the options exercised during the years ended December 31, 2015, 2014 and 2013 were $3,546, $3,339 and $3,431, respectively. The aggregate intrinsic value is calculated as the difference between the per share exercise price and the deemed fair value of the Company’s ordinary shares for each share subject to an option multiplied by the number of shares subject to options at the date of exercise. The Company deemed the fair value of the Company’s ordinary shares to be $22.36, $7.73 and $7.28 per share as of December 31, 2015, 2014, and 2013, respectively. The options outstanding as of December 31, 2015 are as follows: Exercise price Number of options outstanding as of December Weighted average remaining contractual term Number of options exercisable as of December 31, 2015 Weighted average remaining contractual term $ (years) (years) 0.17 1,402,757 0.71 1,402,757 0.71 0.23 440,531 3.42 440,531 3.42 0.38 488,331 4.78 488,331 4.78 3.44 1,779,072 5.88 1,728,710 5.89 6.72 850,401 6.67 642,321 6.66 6.83 92,227 6.95 69,308 6.95 7.03 613,174 7.14 307,309 7.14 7.04 135,992 7.46 67,982 7.46 7.28 167,921 7.65 83,946 7.65 7.48 504,365 8.14 130,509 8.13 7.52 110,560 8.24 29,925 8.23 7.58 52,032 8.49 13,006 8.49 7.73 431,053 8.77 107,755 8.77 14.37 1,616,011 9.16 9,016 8.84 15.60 146,926 9.32 - - 20.20 140,466 9.81 - - 22.00 913,210 9.76 - - 27.50 249,800 9.97 - - 10,134,829 6.56 5,521,406 4.63 In August, 2015, the Company’s board of directors adopted an employee share purchase plan (“ESPP”) subject to shareholder approval, which was obtained in September, 2015. The Company adopted the ESPP to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. The ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company intends to begin offerings under the ESPP at a future date determined by the compensation committee, in its sole discretion. As of December 31, 2015 no shares have been offered under the ESPP. Under the ESPP, initially an aggregate of 830,000 ordinary shares could be purchased by eligible employees who become participants in the ESPP; which amount shall be automatically increased on December 31 of each year during the term of the ESPP to an amount equal to 1% of the total number of ordinary shares outstanding on December 30 of such year unless otherwise determined by the board of directors. On December 31, 2015, the number of shares available for issuance under the ESPP increased from 837,785 shares to 1,667,785 shares. As of December 31, 2015, 1,667,785 ordinary shares are available for grant under the ESPP.

Financial Expenses, Net

Financial Expenses, Net	12 Months Ended
	Dec. 31, 2015
Interest And Debt Expense [Abstract]
Financial Expenses, Net	Note 15: Financial expenses, net Year ended December 31, 2015 2014 2013 Financial expenses: Interest expense $ (2,373 ) $ (41 ) $ (7,158 ) Amortization of credit facility costs (329 ) - (5,432 ) Foreign currency transaction losses (356 ) (104 ) (157 ) Others (177 ) (142 ) (78 ) $ (3,235 ) $ (287 ) $ (12,825 ) Financial income: Interest income $ 84 $ 143 $ 267 Total financial expenses, net $ (3,151 ) $ (144 ) $ (12,558 )

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	Note 16: Basic and diluted net loss per share The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2015 2014 2013 Net loss attributable to ordinary shares as reported $ (111,581 ) $ (80,682 ) $ (77,370 ) Shares used in computing net loss per ordinary share, basic and diluted 30,401,603 12,490,017 11,498,392 Net loss per ordinary share, basic and diluted $ (3.67 ) $ (6.46 ) $ (6.73 ) For the years ended December 31, 2015, 2014 and 2013, all outstanding preferred shares, options and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.

Subcontractor

Subcontractor	12 Months Ended
	Dec. 31, 2015
Subcontractor [Abstract]
Subcontractor	Note 17: Subcontractor The Company is dependent upon sole source suppliers for certain key components used in its delivery systems. The Company’s management believes that in most cases other suppliers could provide similar components at comparable terms. A change of suppliers which requires FDA or other regulatory approval, however, could cause a material delay in manufacturing and a possible loss of sales, which could adversely affect the Company’s operating results and financial position.

Supplemental Information

Supplemental Information	12 Months Ended
	Dec. 31, 2015
Geographic Areas Long Lived Assets [Abstract]
Supplemental Information	Note 18: Supplemental information The following table presents long-lived assets by location: December 31, 2015 2014 United States 6,600 3,468 Switzerland 4,204 1,259 Israel $ 1,376 $ 1,009 Others 401 13 $ 12,581 $ 5,749 The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2015 2014 2013 United States 30,961 14,951 10,330 Europe, Israel and Japan 2,126 $ 539 $ 29 $ 33,087 $ 15,490 $ 10,359

Significant Accounting Polici27

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Use of Estimates	a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates.
Financial Statements in U.S. Dollars	b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S. dollar. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with Accounting Standards Codification No. 830-10, “Foreign Currency Matters.” All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as appropriate.
Principles of Consolidation	c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.
Cash Equivalents	d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less at the date acquired.
Short-term Investments and Restricted Cash	e. Short-term investments and restricted cash: 1. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, “Investments-Debt and Equity Securities.” Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2015 and 2014, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any other than temporary impairment losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2015, no impairment losses other than temporary impairment losses have been identified. 2. Restricted cash: The Company has restricted cash used as security for bank guarantees related to the use of Company credit cards.
Inventories	f. Inventories: Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. The Company regularly evaluates the ability to realize the value of inventory. If actual demand for the Company’s delivery systems deteriorates, or market conditions are less favorable than those projected, inventory write-offs may be required. There were no inventory write-offs for the years ended December 31, 2015, 2014 and 2013.
Property and Equipment	g. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life
Impairment of Long-Lived Assets	i. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, “Property, Plant and Equipment,” whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2015, no impairment losses have been identified.
Other Long-Term Assets	j. Other long-term assets: Long term lease deposits in respect of office rent and vehicles under operating leases and restricted deposits are presented in other long-term assets.
Revenue Recognition	k. Revenue recognition: The TTFields delivery system (“System”) for GBM, Optune, is comprised of two main components: (1) an Electric Field Generator (the “device”) and (2) Transducer Arrays and related accessories that are disposable supplies to the device (“disposables”). Title is retained by the Company for the device and the patient is provided replacement disposables and technical support for the device during the rental period. The device and disposables are always supplied and functioning together and are not sold on a standalone basis. Revenues are recognized when persuasive evidence of an arrangement exists, delivery of the system has occurred, the price is fixed or determinable and collectability is reasonably assured. The evidence of an arrangement generally consists of a prescription, a patient service agreement and the verification of eligibility and insurance with the patient’s third-party insurance company (“payer”). The Company generally bills third-party payers a monthly fee for use of the System by patients. As such, the Company takes assignment of benefits and risk of collection from the third-party payer. Patients have out-of-pocket costs for the amount not covered by their payer and the Company bills the patient directly for the amounts of their co-pays and deductible, subject to the Company’s patient assistance programs. For the reported periods, all revenues are recognized when cash is collected assuming that all other revenue recognition criteria have been met, as the price is not fixed or determinable and the collectability cannot be reasonably assured. The price is not fixed or determinable since the Company does not have sufficient history with payers to reliably estimate their individual payment patterns and as such cannot reliably estimate the amount that would be ultimately collected. Once sufficient history is established and the Company can reliably estimate the amounts that would be ultimately collected per payer/payer group and the above criteria are met, the Company will recognize revenues from the use of the System on an accrual basis ratably over the lease term. Revenues are presented net of indirect taxes, which include excise tax of $1,457 , $1,010, and $584 for the years ended December 31, 2015, 2014 and 2013, respectively, and other indirect tax of $818, $266 and $300 for the years ended December 31, 2015, 2014 and 2013, respectively.
Charity Care	l. Charitable care: The Company provides Optune to patients who meet certain criteria under its charitable care policy without charge. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were: $1,376, $836 and $254 for the years ended December 31, 2015, 2014 and 2013, respectively. These estimates were determined by applying a ratio of costs to gross charges multiplied by the Company's gross charitable care charges.
Research, Development and Clinical Trials	m. Research, development and clinical trials: Research, development and clinical trials, including direct and allocated expenses are expensed as incurred.
Shipping and Handling Costs	n. Shipping and handling costs: The Company does not bill its customers for shipping and handling costs associated with shipping its delivery systems to its customers. These direct shipping and handling costs of $1,385, $553 and $431 for the years ended December 31, 2015, 2014 and 2013, respectively are included in selling and marketing costs.
Accounting for Share-based Payments	o. Accounting for share-based payments: The Company accounts for share-based compensation in accordance with ASC 718, “Compensation—Stock Compensation.” ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation costs net of a forfeiture rate only for those shares expected to vest using the accelerated method over the requisite service period of the award, which is generally the option vesting term of four years. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price expected, expected volatility and the expected option term. Prior to the IPO, the fair value of ordinary shares underlying the options was historically determined by management and the board of directors. Because there was no public market for the Company’s ordinary shares, the board of directors determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including operating and financial performance, the lack of liquidity of share capital, general and industry specific economic outlook and valuations performed amongst other factors. For the period from January 1, 2015 through the IPO and for the two years ended December 31, 2014, the Company’s board of directors determined the fair value of ordinary shares for the reported periods, among other factors, based on valuations performed using the hybrid method, which is the hybrid between the probability weighted expected return method (PWERM) and the option pricing method, as the Company began to consider IPO activities commencing in January 2012. The computation of expected volatility is based on actual historical share price volatility of comparable companies. Expected term of options granted is calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms.
Fair Value of Financial Instruments	p. Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the long-term loans approximate fair value. The Company accounts for certain assets and liabilities at fair value under ASC 820, “Fair Value Measurements and Disclosures.” Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument are categorized as Level 3.
Basic and Diluted Net Loss Per Share	q. Basic and diluted net loss per share: The Company applies the two class method as required by ASC 260-10, “Earnings Per Share.” ASC 260-10 requires the income or loss per share for each class of shares (ordinary and preferred shares) to be calculated assuming 100% of the Company’s earnings are distributed as dividends to each class of shares based on their contractual rights. No dividends were declared or paid during the reported periods. According to the provisions of ASC 260-10, the Company’s preferred shares are not participating securities in losses and, therefore, are not included in the computation of net loss per share. Basic and diluted net loss per share is computed based on the weighted average number of ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period, in accordance with ASC 260-10. Basic and diluted net loss per ordinary share was the same for each period presented as the inclusion of all potential ordinary shares (all preferred shares, options and warrants) outstanding was anti-dilutive.
Income Taxes	r. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes.” ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is “more likely than not” to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense.
Concentration of Risks	s. Concentration of risks: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term investments. Cash and cash equivalents and restricted cash are invested in major banks or financial institutions in Jersey, the United States, Israel, Luxemburg, Switzerland, Japan and Germany. Such investments may be in excess of insured limits and are not insured in other jurisdictions. Generally, these investments may be redeemed upon demand and, therefore, bear minimal risk. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. In 2015, two payers represented $5,595 and $2,512 or 17% and 8% of net revenues, respectively. In 2014, the same two payers represented $2,372 and $2,014 or 15% and 12% of net revenues, respectively and in 2013, the same two payers represented $2,056 and $1,160 or 18% and 10% of net revenues, respectively.
Severance Pay	t. Severance pay: The majority of the Company’s employees in Israel have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (“Section 14”). Pursuant to Section 14, the Company’s employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. Neither severance pay liability nor severance pay fund under Section 14 for such employees is recorded on the Company’s consolidated balance sheet. With regard to employees in Israel that are not subject to Section 14, the Company’s liability for severance pay is calculated pursuant to Israeli Severance Pay Law, based on the most recent salary of the relevant employees multiplied by the number of years of employment as of the balance sheet date. These employees are entitled to one month’s salary for each year of employment or a portion thereof. The Company’s liability for these employees is fully provided for through monthly deposits to the employees’ pension and management insurance policies and an accrual. The value of these deposits is recorded as an asset on the Company’s consolidated balance sheet. The carrying value of the deposited funds is based on the cash surrender value and includes profits accumulated up to the balance sheet date. The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Israeli Severance Pay Law. Severance pay expense for the years ended December 31, 2015, 2014 and 2013 amounted to $356, $307 and $288, respectively.
Retirement and Pension Plans	u. Retirement and pension plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. The Company does not make any matching contributions to the plan. The Company has a defined benefit plan with a pension fund for its Swiss employees, whereby the employee and the Company contribute to the pension fund. The Company accounts for its obligation, in accordance with ASC 715, "Compensation – Retirement Benefits" (see note 9). The pension expense for the years ended December 31, 2015, 2014 and, 2013 was $404, $205 and $70, respectively.
Contingent Liabilities	v. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2015 and 2014, the Company was not a party to any ligation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.
Other Comprehensive Loss	w. Other comprehensive loss: The Company accounts for comprehensive loss in accordance with ASC 220, "Comprehensive Income". This statement establishes standards for the reporting and display of comprehensive loss and its components. Comprehensive loss generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive loss, net of taxes, at December 31, 2015 relates to a pension liability.
Recently Issued Accounting Pronouncement	x. Recently issued accounting pronouncements: In November 2015, the Financial Accounting Standards Board ("FASB") issued an accounting standards update for income taxes, which requires deferred tax assets and liabilities to be classified as noncurrent on the consolidated balance sheets. The new accounting guidance is effective for annual reporting periods beginning after December 15, 2016 and interim periods therein. Early adoption is permitted for all entities as of the beginning of interim or annual reporting periods. The Company early adopted the new guidance for the year ended December 31, 2015 and has applied the amendment on a prospective basis. In April 2015, the FASB amended the existing accounting standards for imputation of interest. The amendments require that debt issuance costs related to a recognized debt liability be presented on the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. The Company is required to adopt the guidance in the first quarter of fiscal 2017. Early adoption is permitted. The amendments should be applied retrospectively with the adjusted balance sheet of each individual period presented, in order to reflect the period-specific effects of applying the new guidance. The Company early adopted the new guidance for the year ended December 31, 2015.The adoption of this standard resulted in a reclassification of the debt issuance costs of $1.4 million for the year ended December 31, 2015, from Other long-term assets to Long-term loan, net of discount and issuance costs on the consolidated balance sheet. There was no impact to the consolidated statements of operations, comprehensive loss or cash flows. In May 2014, the FASB amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued an accounting standard update for a one-year deferral of the effective date, with an option of applying the standard on the original effective date, which for the Company is the first quarter of fiscal 2017. In accordance with this deferral, the Company is required to adopt these amendments no later than the first quarter of fiscal 2018. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is continuing to evaluate the impact of these amendments and the transition alternatives on its consolidated financial statements.
Field Equipment Under Operating Leases
Significant Accounting Policies [Line Items]
Property and Equipment	h. Field equipment under operating leases: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment which was determined to be two years. Field equipment consists of equipment being utilized under rental agreements accounted for in accordance with ASC 840 on a monthly basis as an operating lease, as well as “service pool” equipment. Service pool equipment is equipment owned and maintained by the Company that is swapped for equipment that needs repairs or maintenance by the Company while being rented by a patient. The Company records a provision for any excess, lost or damaged equipment when warranted based on an assessment of the equipment. Write-downs for equipment are included in cost of revenues. During the years ended December 31, 2015, 2014 and 2013, write downs for $36, $12 and $19, respectively, had been identified.

Significant Accounting Polici28

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Property and Equipment at Cost Using Straight-Line Method	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life

Cash and Cash Equivalents and29

Cash and Cash Equivalents and Short Term Investments (Tables)	12 Months Ended
	Dec. 31, 2015
Cash And Cash Equivalents [Abstract]
Summary of Cash and Cash Equivalents	a. Cash and cash equivalents: December 31, 2015 2014 Cash $ 75,421 $ 47,614 Money market funds 44,002 - U.S. treasury bills - 9,999 Total cash and cash equivalents $ 119,423 $ 57,613

Receivables and Prepaid Expen30

Receivables and Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Receivables And Prepaid Expenses [Abstract]
Schedule of Receivables and Prepaid Expenses	December 31, 2015 2014 Advances and receivables from suppliers $ 7,323 $ 4,262 Government authorities 1,955 501 Prepaid expenses 1,290 853 Others 231 95 $ 10,799 $ 5,711

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	December 31, 2015 2014 Raw materials $ 3,518 $ 526 Work in process 4,618 1,280 Finished goods 5,458 1,640 $ 13,594 $ 3,446

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment Net	December 31, 2015 2014 Cost: Computers and laboratory equipment $ 6,734 $ 3,745 Office furniture 1,245 995 Production equipment 857 - Leasehold improvements 1,653 1,343 Total cost $ 10,489 $ 6,083 Accumulated depreciation and amortization (3,937 ) (2,351 ) Depreciated cost $ 6,552 $ 3,732

Field Equipment, Net (Tables)

Field Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Field Equipment [Abstract]
Schedule of Field Equipment, Net	December 31, 2015 2014 Field equipment $ 9,226 $ 3,942 Less: accumulated depreciation (3,197 ) (1,925 ) Field equipment, net $ 6,029 $ 2,017

Other Payables and Accrued Ex34

Other Payables and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables And Accruals [Abstract]
Schedule of Other Payables and Accrued Expenses	December 31, 2015 2014 Employees and payroll accruals $ 8,258 $ 5,846 Taxes payable and others 2,850 693 Provision for settlement - 1,000 Other 764 97 $ 11,872 $ 7,636

Employee benefit obligations (T

Employee benefit obligations (Tables)	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Schedule of Targeted Allocation of Plan Assets	The targeted allocation for these funds is as follows: Asset Allocation by Category as of December 31, 2015: Asset Category: Asset allocatio n Debt Securities 75 Real Estate 16 Equity Securities 3 Others 6 Total 100
Schedule of Change in Benefit Obligations	The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2015: December 31, 2015 Change in Benefit Obligation Projected benefit obligation at beginning of year $ - Interest cost 47 Company service cost 312 Employee contributions 189 Prior service cost 158 Benefits paid 4,023 Actuarial loss 1,494 Projected benefit obligation at end of year $ 6,223 Change in Plan Assets Fair value of plan assets at beginning of year $ - Actual return on plan assets (63 ) Employer contributions 284 Employee contributions 189 Benefits paid 4,023 Fair value of plan assets at end of year $ 4,433 Funded Status at End of year Excess of obligation over assets $ (1,790 ) Change in Accrued Benefit Liability Accrued benefit asset/(liability) at beginning of year $ - Company contributions made during year 284 Net periodic benefit cost for year (404 ) Net decrease in accumulated other comprehensive loss (1,670 ) Accrued benefit liability at end of year $ (1,790 ) December 31, 2015 Non - current plan assets $ 4,433 Non - current liability 6,223 Accrued benefit liability at end of year $ (1,790 ) Projected Benefit Payments 2016 $ 8 2017 13 2018 19 2019 25 2020 32 2021 - 2024 $ 264
Schedule of Fair Value the Plan Assets	The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2015. The level of inputs used to measure fair value was Level 2. Year December 31, 2015 Net Periodic Benefit Cost Service cost $ 312 Interest cost 47 Expected return on plan assets (38 ) Amortization of prior service costs 14 Amortization of transition obligation 69 Total net periodic benefit cost $ 404 Weighted average assumptions: Discount rate as of December 31 1.00% Expected long-term rate of return on assets 1.00% Rate of compensation increase 1.00% Mortality and disability assumptions BV G (*) Mortality data used for actuarial calculation.

Other Long-term Liabilities (Ta

Other Long-term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Schedule of Other Long-term Liabilities	December 31, 2015 2014 Deferred rent liability $ 785 $ 590 Leasehold improvements financing and other (see a and b below) 254 321 Unrecognized tax benefits (Note 13e) 1,565 308 Provision for settlement (Note 14c) - 867 Other 131 - $ 2,735 $ 2,086
Schedule of Leasehold Improvement Financing Repayments	The above principal leasehold improvement financing repayments as of December 31, 2015 are as follows: 2016 $ 63 2017 69 2018 73 2019 23 2020 24 Thereafter 65 317 Less: current portion of long-term loans (63 ) Long-term loans, net of current portion $ 254

Commitments and Contingent Li37

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases	Future minimum lease payments under non-cancelable operating leases as of December 31, 2015, are as follows: 2016 $ 2,320 2017 2,171 2018 1,152 2019 987 2020 591 Thereafter 1,261 $ 8,482

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Loss before Income Taxes	a. The provision (benefit) for income taxes is comprised of: Loss before income taxes: Year ended December 31, 2015 2014 2013 United States (U.S.) $ (55,087 ) $ (22,015 ) $ (15,698 ) Non-U.S. (52,060 ) (58,285 ) (61,319 ) $ (107,147 ) $ (80,300 ) $ (77,017 )
Schedule of Components of Income Tax Expense (Benefit)	a. The provision (benefit) for income taxes is comprised of: Income tax expense (benefit): Year ended December 31, 2015 2014 2013 Current: United States $ 891 $ 65 $ (18 ) Non-U.S. 3,678 324 308 Total current 4,569 389 290 Deferred: Non-U.S. (135 ) (7 ) 63 Total deferred $ (135 ) $ (7 ) $ 63 $ 4,434 $ 382 $ 353
Reconciliation of Provision for Income Taxes	A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2015 2014 2013 Loss before income taxes $ (107,147 ) $ (80,300 ) $ (77,017 ) Statutory tax rate 35 % 35 % 35 % Notional U.S. federal income taxes at statutory rate $ (37,501 ) $ (28,105 ) $ (26,956 ) Non-deductible expenses 2,621 1,242 1,411 Foreign tax rate differential 18,573 20,261 20,965 Change in valuation allowance 19,550 7,226 4,727 Unrecognized tax expense (benefit) 1,257 (242 ) 206 Other (66 ) - - Income tax expenses $ 4,434 $ 382 $ 353 Effective tax rate -4.14 % -0.48 % -0.46 %
Schedule of Significant Components of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax assets: Allowance for doubtful accounts $ 11,504 $ 4,001 Revenue recognition (timing differences) 21,972 9,042 Net operating loss carryforwards 347 850 Other temporary differences 952 482 Total gross deferred tax assets $ 34,775 $ 14,375 Less: valuation allowance (33,476 ) (13,926 ) Total deferred tax assets $ 1,299 $ 449 Deferred tax liabilities: Fixed assets 1,008 442 Total gross deferred tax liabilities $ 1,008 $ 442 Net deferred tax assets $ 291 $ 7
Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2015 2014 Balance at beginning of the year $ 308 $ 549 Additions for tax positions related current year 848 79 Additions for tax positions related to prior years 409 - Reduction related to lapse of applicable statute of limitations - (320 ) Balance at the end of the year $ 1,565 $ 308

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2015
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Schedule of Share Capital	Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2015 2014 Ordinary shares no par value 83,778,581 13,431,414 Series A Convertible Preferred shares no par value - 4,177,235 Series B Convertible Preferred shares no par value - 4,590,439 Series C Convertible Preferred shares no par value - 2,261,666 Series D Convertible Preferred shares no par value - 4,451,913 Series E Convertible Preferred shares no par value - 7,790,861 Series F Convertible Preferred shares no par value - 12,864,362 Series G Convertible Preferred shares no par value - 5,106,269 Series H Convertible Preferred shares no par value - 4,073,020 Series I Convertible Preferred shares no par value - 13,360,252 Total - 58,676,017
Schedule of Warrants to Purchase Ordinary Shares were Issued to Purchase of Convertible Preferred Shares	Significant terms of the warrants to purchase ordinary shares that were issued to purchasers of the Series B, C, D and E Convertible Preferred shares are as follows as of December 31, 2015 and 2014: Warrants for ordinary shares Exercise per share Expiration date 2015 2014 October 11, 2015 (1) - 565,411 3.54 May 8, 2016 (1) 1,108,050 1,112,983 3.59 July 31, 2017 556,678 556,678 3.59 January 22, 2018 556,678 556,678 3.59 July 21, 2018 834,355 834,355 3.59 3,055,761 3,626,105 ( 1 ) Warrants to purchase 570,344 ordinary shares were exercised in 2015, resulting in the issuance of 570,344 ordinary shares.
Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model	The fair value of share-based awards was estimated using the Black-Scholes option-pricing model for all grants, with the following underlying assumptions: Year ended December 31, 2015 2014 2013 Expected term (years) 6.25 6.25 6.25 Expected volatility 59%-65.8% 73.1%-75.3% 70.4%-75.9% Risk-free interest rate 1.74%-2.05% 1.9%-2.3% 1.4%-2.0% Dividend yield 0% 0% 0%
Schedule of Stock Options to Purchase Ordinary Shares	A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2015 and changes during the year ended on that date is presented below: Year ended December 31, 2015 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 7,426,159 3.98 Granted 3,108,393 18.01 Exercised (183,911 ) 3.08 Forfeited and cancelled (215,812 ) 8.81 Outstanding at end of year 10,134,829 8.20 144,776 Exercisable options 5,521,406 3.04 106,684 Vested and expected to vest 10,007,130 8.11 143,835
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards	The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2015, 2014 and 2013, was comprised as follows: Year ended December 31, 2015 2014 2013 Cost of revenues $ 174 $ 32 $ 52 Research, development and clinical trials 2,529 820 1,137 Sales and marketing 2,496 1,104 791 General and administrative 6,661 2,668 3,140 Total share-based compensation expense $ 11,860 $ 4,624 $ 5,120
Schedule of Stock Option Outstanding	The options outstanding as of December 31, 2015 are as follows: Exercise price Number of options outstanding as of December Weighted average remaining contractual term Number of options exercisable as of December 31, 2015 Weighted average remaining contractual term $ (years) (years) 0.17 1,402,757 0.71 1,402,757 0.71 0.23 440,531 3.42 440,531 3.42 0.38 488,331 4.78 488,331 4.78 3.44 1,779,072 5.88 1,728,710 5.89 6.72 850,401 6.67 642,321 6.66 6.83 92,227 6.95 69,308 6.95 7.03 613,174 7.14 307,309 7.14 7.04 135,992 7.46 67,982 7.46 7.28 167,921 7.65 83,946 7.65 7.48 504,365 8.14 130,509 8.13 7.52 110,560 8.24 29,925 8.23 7.58 52,032 8.49 13,006 8.49 7.73 431,053 8.77 107,755 8.77 14.37 1,616,011 9.16 9,016 8.84 15.60 146,926 9.32 - - 20.20 140,466 9.81 - - 22.00 913,210 9.76 - - 27.50 249,800 9.97 - - 10,134,829 6.56 5,521,406 4.63

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Interest And Debt Expense [Abstract]
Schedule of Financial Expenses, Net	Year ended December 31, 2015 2014 2013 Financial expenses: Interest expense $ (2,373 ) $ (41 ) $ (7,158 ) Amortization of credit facility costs (329 ) - (5,432 ) Foreign currency transaction losses (356 ) (104 ) (157 ) Others (177 ) (142 ) (78 ) $ (3,235 ) $ (287 ) $ (12,825 ) Financial income: Interest income $ 84 $ 143 $ 267 Total financial expenses, net $ (3,151 ) $ (144 ) $ (12,558 )

Basic and Diluted Net Loss Pe41

Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Ordinary Share	The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2015 2014 2013 Net loss attributable to ordinary shares as reported $ (111,581 ) $ (80,682 ) $ (77,370 ) Shares used in computing net loss per ordinary share, basic and diluted 30,401,603 12,490,017 11,498,392 Net loss per ordinary share, basic and diluted $ (3.67 ) $ (6.46 ) $ (6.73 )

Supplemental Information (Table

Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2015
Geographic Areas Long Lived Assets [Abstract]
Schedule of Long-Lived Assets by Location	The following table presents long-lived assets by location: December 31, 2015 2014 United States 6,600 3,468 Switzerland 4,204 1,259 Israel $ 1,376 $ 1,009 Others 401 13 $ 12,581 $ 5,749
Schedule of Revenues by Geographic Region	The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2015 2014 2013 United States 30,961 14,951 10,330 Europe, Israel and Japan 2,126 $ 539 $ 29 $ 33,087 $ 15,490 $ 10,359

Organization and Basis of Pre43

Organization and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Oct. 07, 2015USD ($)shares	Sep. 30, 2015$ / shares	Dec. 31, 2015$ / shares	Sep. 30, 2015£ / shares	Dec. 31, 2014$ / shares
Organization And Basis Of Presentation [Line Items]
Ordinary shares no par value
preferred shares no par value
Share split ratio		5.913
Preferred stock, par value | (per share)			$ 0	£ 0.01	$ 0
Common stock, par value | (per share)			$ 0	£ 0.01	$ 0
Ordinary Shares | IPO
Organization And Basis Of Presentation [Line Items]
Issuance of shares, net (in shares) | shares	7,876,195
Proceeds from issuance of ordinary shares | $	$ 157,534

Significant Accounting Polici44

Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Significant Accounting Policies [Line Items]
Other than temporary impairment losses on short-term investments	$ 0
Inventory write-offs	0	$ 0	$ 0
Impairment of long-lived assets	0
Excise taxes	1,457,000	1,010,000	584,000
Other indirect taxes	818,000	266,000	300,000
Cost related to charitable care	1,376,000	836,000	254,000
Shipping and handling costs	$ 1,385,000	$ 553,000	$ 431,000
Expected dividend yield	0.00%	0.00%	0.00%
Dividends declared	$ 0
Dividends paid	0
Net revenues	$ 33,087,000	$ 15,490,000	$ 10,359,000
Monthly salary contribution rate by employer	8.33%
Severance costs	$ 356,000	307,000	288,000
Pension expense	404,000	205,000	70,000
Recent accounting pronouncement resulted in reclassification of debt issuance cost	1,400
Sales Revenue Net | Customer One | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Net revenues	$ 5,595,000	$ 2,372,000	$ 2,056,000
Concentration risk percentage	17.00%	15.00%	18.00%
Sales Revenue Net | Customer Two | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Net revenues	$ 2,512,000	$ 2,014,000	$ 1,160,000
Concentration risk percentage	8.00%	12.00%	10.00%
Employee Stock Option
Significant Accounting Policies [Line Items]
Share-based award requisite service period	4 years
Expected dividend yield	0.00%
Field Equipment Under Operating Leases
Significant Accounting Policies [Line Items]
Property and equipment useful life	2 years
Equipment write-downs included in cost of revenue	$ 36,000	$ 12,000	$ 19,000

Property and Equipment at Cost

Property and Equipment at Cost Using Straight-Line Method (Details)	12 Months Ended
	Dec. 31, 2015
Computers and laboratory equipment | Minimum
Property Plant And Equipment [Line Items]
Straight line depreciation rate	15.00%
Computers and laboratory equipment | Maximum
Property Plant And Equipment [Line Items]
Straight line depreciation rate	33.00%
Office furniture | Minimum
Property Plant And Equipment [Line Items]
Straight line depreciation rate	6.00%
Office furniture | Maximum
Property Plant And Equipment [Line Items]
Straight line depreciation rate	33.00%
Production equipment
Property Plant And Equipment [Line Items]
Straight line depreciation rate	20.00%
Leasehold improvements
Property Plant And Equipment [Line Items]
Straight line depreciation useful life	Over the shorter of the term of the lease or its useful life

Cash and Cash Equivalents and46

Cash and Cash Equivalents and Short Term Investments - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 119,423	$ 57,613	$ 175,894	$ 34,891
Cash
Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	75,421	47,614
Money market funds
Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 44,002
U.S. treasury bills
Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents		$ 9,999

Cash and Cash Equivalents and47

Cash and Cash Equivalents and Short Term Investments - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Investments Debt And Equity Securities [Abstract]
Short-term investments	$ 150,001	$ 44,999
Estimated fair value of short-term investments	$ 149,978	$ 44,999

Receivables and Prepaid Expen48

Receivables and Prepaid Expenses - Schedule of Receivables and Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Receivables And Prepaid Expenses [Abstract]
Advances and receivables from suppliers	$ 7,323	$ 4,262
Government authorities	1,955	501
Prepaid expenses	1,290	853
Others	231	95
Receivables and prepaid expenses	$ 10,799	$ 5,711

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 3,518	$ 526
Work in process	4,618	1,280
Finished goods	5,458	1,640
Total	$ 13,594	$ 3,446

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,489	$ 6,083
Accumulated depreciation and amortization	(3,937)	(2,351)
Depreciated cost	6,552	3,732
Computers and laboratory equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,734	3,745
Office furniture
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,245	995
Production equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	857
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,653	$ 1,343

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Accumulated computer software amortization	$ 2,803
Computer software amortization	250
Property and Equipment
Property Plant And Equipment [Line Items]
Depreciation expense	$ 1,348	$ 886	$ 520

Field Equipment, Net - Schedule

Field Equipment, Net - Schedule of Field Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Field Equipment [Abstract]
Field equipment	$ 9,226	$ 3,942
Less: accumulated depreciation	(3,197)	(1,925)
Field equipment, net	$ 6,029	$ 2,017

Field Equipment, Net - Addition

Field Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Field equipment
Field Equipment [Line Items]
Depreciation	$ 1,555	$ 1,076	$ 696

Other Payables and Accrued Ex54

Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables And Accruals [Abstract]
Employees and payroll accruals	$ 8,258	$ 5,846
Taxes payable and others	2,850	693
Provision for settlement		1,000
Other	764	97
Other payables and accrued expenses	$ 11,872	$ 7,636

Employee benefit obligations -

Employee benefit obligations - Schedule of Asset Allocation by Category (Details)	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	100.00%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	75.00%
Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	16.00%
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	3.00%
Others
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	6.00%

Employee benefit obligations 56

Employee benefit obligations - Net Funded Status (Details) - 12 months ended Dec. 31, 2015 - USD ($) $ in Thousands	Total	Total
Change in Benefit Obligation
Interest cost	$ 47
Company service cost	312
Employee contributions	189
Prior service cost	158
Benefits paid	4,023
Actuarial loss	1,494
Projected benefit obligation at end of year	6,223
Change in Plan Assets
Actual return on plan assets	(63)
Employer contributions	284
Employee contributions	189
Benefits paid	4,023
Fair value of plan assets at end of year	4,433
Funded Status at End of year
Excess of obligation over assets		$ (1,790)
Change in Accrued Benefit Liability
Company contributions made during year	284
Net periodic benefit cost for year	(404)
Net decrease in accumulated other comprehensive loss	(1,670)
Accrued benefit liability at end of year	(1,790)
Non - current plan assets		4,433
Non - current liability		6,223
Accrued benefit liability at end of year	$ (1,790)	(1,790)
Projected Benefit Payments
2,016		8
2,017		13
2,018		19
2,019		25
2,020		32
2021 - 2024		$ 264

Employee benefit obligations 57

Employee benefit obligations - Net Periodic Benefit Cost (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Net Periodic Benefit Cost
Company service cost	$ 312
Interest cost	47
Expected return on plan assets	(38)
Amortization of prior service costs	14
Amortization of transition obligation	69
Total net periodic benefit cost	$ 404
Weighted average assumptions:
Discount rate as of December 31	1.00%
Expected long-term rate of return on assets	1.00%
Rate of compensation increase	1.00%
Mortality and disability assumptions	BVG 2010 GT

Long - Term Loan, Net of Disc58

Long - Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Line Of Credit Facility [Line Items]
Warrants issued to purchase of preferred shares			975,644
Exercise price per share			$ 18.77
Financial expenses, net			$ 3,151,000	$ 144,000	$ 12,558,000
Credit Agreement
Line Of Credit Facility [Line Items]
Line of credit facility, current borrowing capacity		$ 52,000,000
Fair value of warrants converted to shareholders equity			2,864,000
Total discount amount			4,927,000
Original issuance discount amount			2,000,000
Amortization of deferred issuance costs			$ 500,000
Repayment of outstanding borrowing capacity					58,000,000
Financial expenses, net					$ 12,577,000
Credit Agreement | Credit Facility
Line Of Credit Facility [Line Items]
Debt agreement, maturity period		3 years
Accrued interest charge, capitalized as additional principal			11.00%
Credit Agreement | LIBOR
Line Of Credit Facility [Line Items]
Basis spread on variable rate			1.50%
Credit Agreement | LIBOR | Floor rate
Line Of Credit Facility [Line Items]
Interest on the outstanding loan			0.50%
Credit Agreement | Preferred H Shares
Line Of Credit Facility [Line Items]
Warrants issued to purchase of preferred shares		975,644
Exercise price per share		$ 18.77
Term Loan
Line Of Credit Facility [Line Items]
Debt agreement, maturity period	5 years
Line of credit facility, current borrowing capacity	$ 25,000,000
Interest on the outstanding loan			10.00%
Line of credit facility, maximum borrowing capacity	$ 100,000,000
Line of credit facility, remaining borrowing capacity			$ 75,000,000
Funding fees payable			1.50%
Prepayment fee percent			0.75%
Due date of outstanding principal loan			Jan. 31, 2020
Frequency of payments			Quarterly
Term Loan | Other Long-term Assets
Line Of Credit Facility [Line Items]
Original issuance discount amount			$ 491,000
Additional issuance costs			$ 1,739,000
Term Loan | First Year
Line Of Credit Facility [Line Items]
Prepayment fee percent			3.00%
Term Loan | Second Year
Line Of Credit Facility [Line Items]
Prepayment fee percent			2.00%
Term Loan | Third Year
Line Of Credit Facility [Line Items]
Prepayment fee percent			1.00%

Other Long-term Liabilities - S

Other Long-term Liabilities - Schedule of Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]
Deferred rent liability	$ 785	$ 590
Leasehold improvements financing and other (see a and b below)	254	321
Unrecognized tax benefits	1,565	308	$ 549
Provision for settlement		867
Other	131
Other long-term liabilities	$ 2,735	$ 2,086

Other Long-term Liabilities - A

Other Long-term Liabilities - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015CHF (SFr)	Dec. 31, 2014USD ($)	Jan. 31, 2014USD ($)	Jul. 31, 2013CHF (SFr)	May. 31, 2013USD ($)
Facility in Switzerland
Schedule Of Other Long Term Liabilities [Line Items]
Line of credit facility, maximum borrowing capacity | SFr				SFr 400,000
Line of credit	SFr 220,000	$ 232
Principal and interest payment, start date	Jan. 1, 2014
Principal and interest payment, end date	Dec. 31, 2018
Line of credit facility, Interest rate	5.00%
Facility in the U.S.
Schedule Of Other Long Term Liabilities [Line Items]
Line of credit | $			$ 226		$ 226
Principal and interest payment, start date	Jun. 1, 2013
Principal and interest payment, end date	May 1, 2023
Line of credit facility, Interest rate	7.00%

Other Long-term Liabilities -61

Other Long-term Liabilities - Schedule of Leasehold Improvement Financing Repayments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
2,016	$ 63
2,017	69
2,018	73
2,019	23
2,020	24
Thereafter	65
Long-term debt	317
Less: current portion of long-term loans	(63)
Long-term loans, net of current portion	$ 254	$ 321

Commitments and Contingent Li62

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Loss Contingencies [Line Items]
Operating lease expiration description	The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2023.
Lease and rental expense	$ 2,194	$ 1,794	$ 1,356
Pledged bank deposits	133	130
Operating Lease Commitments	$ 283	$ 281
Motor Vehicles
Loss Contingencies [Line Items]
Operating lease expiration description	The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2018
Maximum
Loss Contingencies [Line Items]
Operating lease agreements, expiration year	2,023
Maximum | Motor Vehicles
Loss Contingencies [Line Items]
Operating lease agreements, expiration year	2,018

Commitments and Contingent Li63

Commitments and Contingent Liabilities - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,016	$ 2,320
2,017	2,171
2,018	1,152
2,019	987
2,020	591
Thereafter	1,261
Total minimum lease payments	$ 8,482

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Loss before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States (U.S.)	$ (55,087)	$ (22,015)	$ (15,698)
Non-U.S.	(52,060)	(58,285)	(61,319)
Loss before income taxes	$ (107,147)	$ (80,300)	$ (77,017)

Income Taxes - Schedule of Co65

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
United States	$ 891	$ 65	$ (18)
Non-U.S.	3,678	324	308
Total current	4,569	389	290
Deferred:
Non-U.S.	(135)	(7)	63
Total deferred	(135)	(7)	63
Income tax expenses	$ 4,434	$ 382	$ 353

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Statutory tax rate	35.00%	35.00%	35.00%
Tax benefit or expense recognized due to valuation allowance	$ 0
Uncertain tax positions, interest and penalties recognized	26	$ 2	$ 20
Luxemburg
Income Taxes [Line Items]
Net operating losses carryforward	$ 1,200

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (107,147)	$ (80,300)	$ (77,017)
Statutory tax rate	35.00%	35.00%	35.00%
Notional U.S. federal income taxes at statutory rate	$ (37,501)	$ (28,105)	$ (26,956)
Non-deductible expenses	2,621	1,242	1,411
Foreign tax rate differential	18,573	20,261	20,965
Change in valuation allowance	19,550	7,226	4,727
Unrecognized tax expense (benefit)	1,257	(242)	206
Other	(66)
Income tax expenses	$ 4,434	$ 382	$ 353
Effective tax rate	(4.14%)	(0.48%)	(0.46%)

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Allowance for doubtful accounts	$ 11,504	$ 4,001
Revenue recognition (timing differences)	21,972	9,042
Net operating loss carryforwards	347	850
Other temporary differences	952	482
Total gross deferred tax assets	34,775	14,375
Less: valuation allowance	(33,476)	(13,926)
Total deferred tax assets	1,299	449
Deferred tax liabilities:
Fixed assets	1,008	442
Total gross deferred tax liabilities	1,008	442
Net deferred tax assets	$ 291	$ 7

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Balance at beginning of the year	$ 308	$ 549
Additions for tax positions related current year	848	79
Additions for tax positions related to prior years	409
Reduction related to lapse of applicable statute of limitations		(320)
Balance at the end of the year	$ 1,565	$ 308

Share Capital - Schedule of Sha

Share Capital - Schedule of Share Capital (Details) - shares	Dec. 31, 2015	Dec. 31, 2014
Share Capital [Line Items]
Common stock, shares issued	83,778,581	13,431,414
Common stock, shares outstanding	83,778,581	13,431,414
Preferred stock, shares issued	0	58,676,017
Preferred stock, shares outstanding	0	58,676,017
Series A Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		4,177,235
Preferred stock, shares outstanding		4,177,235
Series B Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		4,590,439
Preferred stock, shares outstanding		4,590,439
Series C Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		2,261,666
Preferred stock, shares outstanding		2,261,666
Series D Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		4,451,913
Preferred stock, shares outstanding		4,451,913
Series E Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		7,790,861
Preferred stock, shares outstanding		7,790,861
Series F Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		12,864,362
Preferred stock, shares outstanding		12,864,362
Series G Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		5,106,269
Preferred stock, shares outstanding		5,106,269
Series H Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		4,073,020
Preferred stock, shares outstanding		4,073,020
Series I Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, shares issued		13,360,252
Preferred stock, shares outstanding		13,360,252

Share Capital - Schedule of S71

Share Capital - Schedule of Share Capital (Parenthetical) (Details)	Dec. 31, 2015$ / shares	Sep. 30, 2015£ / shares	Dec. 31, 2014$ / shares
Share Capital [Line Items]
Common stock, par value | (per share)	$ 0	£ 0.01	$ 0
Preferred stock, par value | (per share)	0	£ 0.01	0
Series A Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series B Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series C Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series D Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series E Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series F Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series G Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series H Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	0		0
Series I Convertible Preferred shares
Share Capital [Line Items]
Preferred stock, par value	$ 0		$ 0

Share Capital - Additional Info

Share Capital - Additional Information (Details) - USD ($)	Dec. 31, 2015	Oct. 07, 2015	Mar. 31, 2015	Feb. 28, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2015
Share Capital [Line Items]
Convertible preferred shares conversion ratio					100.00%
Voting rights of ordinary shareholder					one
Settlement agreement date					February 2,015
Common stock, shares issued	83,778,581				83,778,581	13,431,414
Share-based Compensation Cost				$ 0
Warrants issued to purchase of preferred shares					975,644
Exercise price per share	$ 18.77				$ 18.77
Class of Warrant or Right, Date from which Warrants or Rights Exercisable					Jan. 31, 2016
Unrecognized compensation cost	$ 25,008,000				$ 25,008,000
Unrecognized compensation cost expected recognition weighted average period					3 years 4 months 21 days
Weighted average grant date fair values options granted					$ 10.64	$ 5.08	$ 4.59
Weighted average grant date fair values options unvested					$ 8.66	$ 4.26	$ 3.42
Weighted average grant date fair values options unvested amount	4,613,423				4,613,423	2,934,974	3,125,543
Weighted average grant date fair values options vested					$ 3.66	$ 2.89	$ 2.26
Weighted average grant date fair values options vested amount					1,235,880	1,166,974	1,030,933
Weighted average grant date fair values options forfeited and cancelled					$ 5.73	$ 3.59	$ 1.84
Aggregate intrinsic values options exercised					$ 3,546,000	$ 3,339,000	$ 3,431,000
Fair value of ordinary shares	$ 22.36				$ 22.36	$ 7.73	$ 7.28
2003 Plan
Share Capital [Line Items]
Option granted vesting period					4 years
Option granted expiration period					10 years
2013 Plan
Share Capital [Line Items]
Option granted vesting period					4 years
Option granted expiration period					10 years
Increase in shares authorized for issuance available for grants			13,198,224	2,956,500
Ordinary shares available for grants	0				0
2015 Plan
Share Capital [Line Items]
Option granted vesting period					4 years
Option granted expiration period					10 years
Increase in shares authorized for issuance available for grants	16,251,143				16,251,143			12,900,000
Ordinary shares available for grants	14,947,667				14,947,667
Percentage increase in number of shares available for issuance	4.00%
Condition One
Share Capital [Line Items]
Settlement agreement terms					(i) 18 months after signing of the Agreement, (ii) an IPO or (iii) the earlier of consummation of a merger/acquisition (“M&A”) or achievement of a Cumulative Net Sales milestone of $250,000 (as defined pursuant to the Agreement).
Condition Two
Share Capital [Line Items]
Settlement agreement terms					(i) achievement of the Cumulative Net Sales milestone per above or (ii) consummation of a merger or acquisition transaction
Settlement Agreement
Share Capital [Line Items]
Earlier Payment period after agreement				18 months
Net sales milestone				$ 250,000,000
Common stock, shares issued				1,005,210
Ordinary shares granted				1,005,210
Earlier Period for Option Termination				12 months
Stock redeemed or called during period, shares				2,010,420
Cash obligation			$ 2,000,000			$ 2,000,000
Settlement Agreement | General and Administrative
Share Capital [Line Items]
Settlement expense						$ 1,867,000
Settlement Agreement | Condition One
Share Capital [Line Items]
Settlement expense				$ 1,000,000
Settlement additional payment				1,000,000
Settlement additional amount paid				1,000,000
Settlement Agreement | Condition Two
Share Capital [Line Items]
Settlement additional payment				$ 5,500,000
Minimum
Share Capital [Line Items]
Entity listing value of share requirement for qualifying IPO in NYSE or NASDAQ					$ 50,000,000
Entity listing value of share requirement for qualifying IPO in other public stock exchange.					$ 100,000,000
Minimum | Settlement Agreement
Share Capital [Line Items]
Percentage of closing price per share			80.00%
ESPP
Share Capital [Line Items]
Increase in shares authorized for issuance available for grants	830,000				830,000
Ordinary shares available for grants	1,667,785				1,667,785
Percentage of increase in shares outstanding					1.00%
ESPP | Minimum
Share Capital [Line Items]
Increase in shares authorized for issuance available for grants	837,785				837,785
ESPP | Maximum
Share Capital [Line Items]
Increase in shares authorized for issuance available for grants	1,667,785				1,667,785
Ordinary Shares | IPO
Share Capital [Line Items]
Sale of ordinary shares		7,876,195
Proceeds from issuance of ordinary shares		$ 157,534,000
Series I Convertible Preferred shares
Share Capital [Line Items]
Shares issued	13,360,252				13,360,252
Shares issued, price per share	$ 14.53				$ 14.53
Proceeds from issuance of preferred shares, net					$ 191,738,000
Liquidation preference per share	$ 14.53				$ 14.53
Series J Convertible Preferred shares
Share Capital [Line Items]
Shares issued	4,068,500				4,068,500
Shares issued, price per share	$ 23.33				$ 23.33
Proceeds from issuance of preferred shares, net					$ 94,599,000
Liquidation preference per share	23.33				$ 23.33
Share issuance expenses					$ 319,000
Series A Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	1.52				$ 1.52
Series B Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	1.09				1.09
Series C Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	1.77				1.77
Series D Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	1.80				1.80
Series E Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	1.80				1.80
Series F Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	2.23				2.23
Series G Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	8.64				8.64
Series H Convertible Preferred shares
Share Capital [Line Items]
Liquidation preference per share	$ 13.5				$ 13.5

Share Capital - Schedule of War

Share Capital - Schedule of Warrants to Purchase Ordinary Shares that were Issued to Purchase of Convertible Preferred Shares (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrants for ordinary shares	3,055,761	3,626,105
Exercise price per share	$ 18.77
October 11, 2015
Class Of Warrant Or Right [Line Items]
Expiration date	Oct. 11, 2015
Warrants for ordinary shares		565,411
Exercise price per share	$ 3.54
May 8, 2016
Class Of Warrant Or Right [Line Items]
Expiration date	May 8, 2016
Warrants for ordinary shares	1,108,050	1,112,983
Exercise price per share	$ 3.59
July 31, 2017
Class Of Warrant Or Right [Line Items]
Expiration date	Jul. 31, 2017
Warrants for ordinary shares	556,678	556,678
Exercise price per share	$ 3.59
January 22, 2018
Class Of Warrant Or Right [Line Items]
Expiration date	Jan. 22, 2018
Warrants for ordinary shares	556,678	556,678
Exercise price per share	$ 3.59
July 21, 2018
Class Of Warrant Or Right [Line Items]
Expiration date	Jul. 21, 2018
Warrants for ordinary shares	834,355	834,355
Exercise price per share	$ 3.59

Share Capital - Schedule of W74

Share Capital - Schedule of Warrants to Purchase Ordinary Shares that were Issued to Purchase of Convertible Preferred Shares (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2015shares
Class Of Warrant Or Right [Line Items]
Warrants exercised to ordinary shares	570,344
Warrant
Class Of Warrant Or Right [Line Items]
Conversion of preferred shares to ordinary shares	570,344

Share Capital - Schedule of Fai

Share Capital - Schedule of Fair Value of Share Based Awards Using Black-Scholes Option Pricing Model (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (years)	6 years 3 months	6 years 3 months	6 years 3 months
Expected volatility, minimum	59.00%	73.10%	70.40%
Expected volatility, maximum	65.80%	75.30%	75.90%
Risk-free interest rate, minimum	1.74%	1.90%	1.40%
Risk-free interest rate, maximum	2.05%	2.30%	2.00%
Expected dividend yield	0.00%	0.00%	0.00%

Share Capital - Schedule of Sto

Share Capital - Schedule of Stock Options to Purchase Ordinary Shares (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Number of options
Number of options, Outstanding at beginning of year | shares	7,426,159
Number of options, Granted | shares	3,108,393
Number of options, Exercised | shares	(183,911)
Number of options, Forfeited and cancelled | shares	(215,812)
Number of options, Outstanding at ending of year | shares	10,134,829
Number of options, Exercisable options | shares	5,521,406
Number of options, Vested and expected to vest | shares	10,007,130
Weighted average exercise price
Weighted average exercise price, Outstanding at beginning of year | $ / shares	$ 3.98
Weighted average exercise price, Granted | $ / shares	18.01
Weighted average exercise price, Exercised | $ / shares	3.08
Weighted average exercise price, Forfeited and cancelled | $ / shares	8.81
Weighted average exercise price, Outstanding at end of year | $ / shares	8.20
Weighted average exercise price, Exercisable options | $ / shares	3.04
Weighted average exercise price, Vested and expected to vest | $ / shares	$ 8.11
Aggregate intrinsic value
Aggregate intrinsic value, Outstanding at end of year | $	$ 144,776
Aggregate intrinsic value, Exercisable options | $	106,684
Aggregate intrinsic value, Vested and expected to vest | $	$ 143,835

Share Capital - Equity-Based Co

Share Capital - Equity-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 11,860	$ 4,624	$ 5,120
Cost of Revenues
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	174	32	52
Research, Development and Clinical Trials
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	2,529	820	1,137
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	2,496	1,104	791
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 6,661	$ 2,668	$ 3,140

Share Capital - Schedule of S78

Share Capital - Schedule of Stock Option Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number of options outstanding	10,134,829	7,426,159
Options outstanding, weighted average remaining contractual term	6 years 6 months 22 days
Number of options exercisable	5,521,406
Options exercisable, weighted average remaining contractual term	4 years 7 months 17 days
Exercise price 0.17
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 0.17
Number of options outstanding	1,402,757
Options outstanding, weighted average remaining contractual term	8 months 16 days
Number of options exercisable	1,402,757
Options exercisable, weighted average remaining contractual term	8 months 16 days
Exercise price 0.23
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 0.23
Number of options outstanding	440,531
Options outstanding, weighted average remaining contractual term	3 years 5 months 1 day
Number of options exercisable	440,531
Options exercisable, weighted average remaining contractual term	3 years 5 months 1 day
Exercise price 0.38
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 0.38
Number of options outstanding	488,331
Options outstanding, weighted average remaining contractual term	4 years 9 months 11 days
Number of options exercisable	488,331
Options exercisable, weighted average remaining contractual term	4 years 9 months 11 days
Exercise price 3.44
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 3.44
Number of options outstanding	1,779,072
Options outstanding, weighted average remaining contractual term	5 years 10 months 17 days
Number of options exercisable	1,728,710
Options exercisable, weighted average remaining contractual term	5 years 10 months 21 days
Exercise price 6.72
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 6.72
Number of options outstanding	850,401
Options outstanding, weighted average remaining contractual term	6 years 8 months 1 day
Number of options exercisable	642,321
Options exercisable, weighted average remaining contractual term	6 years 7 months 28 days
Exercise price 6.83
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 6.83
Number of options outstanding	92,227
Options outstanding, weighted average remaining contractual term	6 years 11 months 12 days
Number of options exercisable	69,308
Options exercisable, weighted average remaining contractual term	6 years 11 months 12 days
Exercise price 7.03
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.03
Number of options outstanding	613,174
Options outstanding, weighted average remaining contractual term	7 years 1 month 21 days
Number of options exercisable	307,309
Options exercisable, weighted average remaining contractual term	7 years 1 month 21 days
Exercise price 7.04
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.04
Number of options outstanding	135,992
Options outstanding, weighted average remaining contractual term	7 years 5 months 16 days
Number of options exercisable	67,982
Options exercisable, weighted average remaining contractual term	7 years 5 months 16 days
Exercise price 7.28
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.28
Number of options outstanding	167,921
Options outstanding, weighted average remaining contractual term	7 years 7 months 24 days
Number of options exercisable	83,946
Options exercisable, weighted average remaining contractual term	7 years 7 months 24 days
Exercise price 7.48
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.48
Number of options outstanding	504,365
Options outstanding, weighted average remaining contractual term	8 years 1 month 21 days
Number of options exercisable	130,509
Options exercisable, weighted average remaining contractual term	8 years 1 month 17 days
Exercise price 7.52
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.52
Number of options outstanding	110,560
Options outstanding, weighted average remaining contractual term	8 years 2 months 27 days
Number of options exercisable	29,925
Options exercisable, weighted average remaining contractual term	8 years 2 months 23 days
Exercise price 7.58
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.58
Number of options outstanding	52,032
Options outstanding, weighted average remaining contractual term	8 years 5 months 27 days
Number of options exercisable	13,006
Options exercisable, weighted average remaining contractual term	8 years 5 months 27 days
Exercise price 7.73
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 7.73
Number of options outstanding	431,053
Options outstanding, weighted average remaining contractual term	8 years 9 months 7 days
Number of options exercisable	107,755
Options exercisable, weighted average remaining contractual term	8 years 9 months 7 days
Exercise price 14.37
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 14.37
Number of options outstanding	1,616,011
Options outstanding, weighted average remaining contractual term	9 years 1 month 28 days
Number of options exercisable	9,016
Options exercisable, weighted average remaining contractual term	8 years 10 months 2 days
Exercise price 15.60
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 15.60
Number of options outstanding	146,926
Options outstanding, weighted average remaining contractual term	9 years 3 months 26 days
Exercise price 20.20
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 20.20
Number of options outstanding	140,466
Options outstanding, weighted average remaining contractual term	9 years 9 months 22 days
Exercise price 22.00
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 22
Number of options outstanding	913,210
Options outstanding, weighted average remaining contractual term	9 years 9 months 4 days
Exercise price 27.50
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price	$ 27.50
Number of options outstanding	249,800
Options outstanding, weighted average remaining contractual term	9 years 11 months 19 days

Financial Expenses, Net - Sched

Financial Expenses, Net - Schedule of Financial Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Financial expenses:
Interest expense	$ (2,373)	$ (41)	$ (7,158)
Amortization of credit facility costs	(329)	0	(5,432)
Foreign currency transaction losses	(356)	(104)	(157)
Others	(177)	(142)	(78)
Financial expenses	(3,235)	(287)	(12,825)
Financial income:
Interest income	84	143	267
Total financial expenses, net	$ (3,151)	$ (144)	$ (12,558)

Basic and Diluted Net Loss Pe80

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net loss attributable to ordinary shares as reported	$ (111,581)	$ (80,682)	$ (77,370)
Shares used in computing net loss per ordinary share, basic and diluted	30,401,603	12,490,017	11,498,392
Net loss per ordinary share, basic and diluted	$ (3.67)	$ (6.46)	$ (6.73)

Supplemental Information - Sche

Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 12,581	$ 5,749
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	6,600	3,468
Switzerland
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	4,204	1,259
Israel
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	1,376	1,009
Others
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 401	$ 13

Supplemental Information - Sc82

Supplemental Information - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	$ 33,087	$ 15,490	$ 10,359
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	30,961	14,951	10,330
Europe, Israel and Japan
Revenues From External Customers And Long Lived Assets [Line Items]
Net revenues	$ 2,126	$ 539	$ 29